Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Prostatic Neoplasms 2Neoplasms 2Colorectal Neoplasms 2Carcinoma 2Squamous Cell Carcinoma of Head and Neck 1Neoplasms, Glandular and Epithelial 1Neoplasms by Histologic Type 1Neoplasm, Residual 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Castration Resistant Prostate Cancer 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma 1

Interventions

Radiotherapy 26Cisplatin 17Fluorouracil 13Paclitaxel 10Carboplatin 6Chemotherapy, Adjuvant 5Cetuximab 5Immunohistochemistry 4Docetaxel 4Radiotherapy, Intensity-Modulated 3Immunoenzyme Techniques 3Hydroxyurea 3Gemcitabine 3Gefitinib 3Filgrastim 3Bortezomib 3sargramostim 2bintrafusp alfa protein, human 2aldesleukin 2Tetrahydrouridine 2SS1(dsFv)PE38 2Radiotherapy, Conformal 2Polymerase Chain Reaction 2Oxaliplatin 2Neoadjuvant Therapy 2Methotrexate 2Magnetic Resonance Spectroscopy 2Leucovorin 2Gene Expression Profiling 2Fluorodeoxyglucose F18 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Head and Neck Neoplasms × ALT-803 × Clear all
NCT04247282 2025-07-16

Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
21 enrolled 16 charts
Head & Neck

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡